Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2013 2
2015 3
2016 1
2017 2
2018 2
2019 2
2020 2
2021 5
2022 7
2023 7
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study.
Weatherald J, Nathan SD, El-Kersh K, Argula RG, DuBrock HM, Rischard FP, Cassady SJ, Tarver J, Levine DJ, Tapson VF, Deng C, Shen E, Das M, Waxman AB. Weatherald J, et al. Among authors: shen e. BMJ Open Respir Res. 2024 Mar 22;11(1):e002116. doi: 10.1136/bmjresp-2023-002116. BMJ Open Respir Res. 2024. PMID: 38519114 Free PMC article.
Exploring the Interactions between Obesity and Diabetes: Implications for Understanding Metabolic Dysregulation in a Saudi Arabian Adult Population.
Ahmad MS, Minaee N, Serrano-Contreras JI, Kaluarachchi M, Shen EY, Boulange C, Ahmad S, Phetcharaburanin J, Holmes E, Wist J, Albaloshi AH, Alaama T, Damanhouri ZA, Lodge S. Ahmad MS, et al. Among authors: shen ey. J Proteome Res. 2024 Feb 2;23(2):809-821. doi: 10.1021/acs.jproteome.3c00717. Epub 2024 Jan 17. J Proteome Res. 2024. PMID: 38230637
Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.
Shlobin OA, Shen E, Wort SJ, Piccari L, Scandurra JA, Hassoun PM, Nikkho SM, Nathan SD. Shlobin OA, et al. Among authors: shen e. Pulm Circ. 2024 Jan 10;14(1):e12310. doi: 10.1002/pul2.12310. eCollection 2024 Jan. Pulm Circ. 2024. PMID: 38205098 Free PMC article. Review.
38 results